The panel estimated that the prevalence of VVA is 115,000 cases out of 380,000 breast cancer survivors. They also confirmed that the epidemiological findings of a 2014 pharmacoeconomic analysisof a US claims database are applicable to the Italian patient population.
Furthermore, the panel verified an estimated 4.25 additional cases/100/year of urinary tract infection (UTI), 3.68 additional cases of vulvovaginitis, 6.97 additional cases of climacteric symptoms and 3.64 additional cases of bone and joint disorders in breast cancer patients with VVA compared to a non-VVA-matched population.
The panel was also unanimous in stating that depression and the need for psychological counseling are more frequent in VVA patients, and more severe in those who have a history of breast cancer.
To meet the medical needs of the VVA breast cancer population, 33.4 additional gynecological visits/100/year can be anticipated, along with 22.8 additional cancer screenings, 7.07 additional outpatient visits and 5.04 screenings for human papillomavirus.
“In particular, vaginal laser have shown a beneficial effect in treating VVA in breast cancer survivors in the short term, but there is no sufficient data on the long-term treatment,” the authors wrote, whereas ospemifene has demonstrated clinical safety on the breast tissue and thus may be appropriate in women with a previous history of breast cancer.